Curium Invests €32M to Expand Prostate Cancer RLT Production
PARIS, France, June 1, 2026 Curium, a global leader in radiopharmaceuticals and nuclear medicine, has announced a strategic investment...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
PARIS, France, June 1, 2026 Curium, a global leader in radiopharmaceuticals and nuclear medicine, has announced a strategic investment...
BOSTON, May 04, 2026 Aktis Oncology has announced the initiation of a Phase 1b clinical trial evaluating AKY-2519, a...
MELBOURNE, Australia & INDIANAPOLIS, IN, April 30, 2026 Telix Pharmaceuticals has announced encouraging dosimetry results from its Phase 2...
SAN DIEGO, USA, April 16, 2026 Janux Therapeutics, Inc. has announced a key clinical milestone with the first participant...
RARITAN, N.J., February 26, 2026 Johnson & Johnson announced encouraging preliminary results from a Phase 1b clinical study evaluating...
RARITAN, N.J., February 26, 2026 Johnson & Johnson (NYSE: JNJ) announced preliminary Phase 1b clinical results demonstrating promising antitumor...
SYDNEY, Australia, Feb. 23, 2026 — Clarity Pharmaceuticals announced a significant clinical milestone in the ongoing SECuRE Trial, reporting...
BARCELONA, Spain, Oct. 8, 2025 — During the 2025 Annual Congress of the European Association of Nuclear Medicine (EANM...
